LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) will present new clinical data on its investigational therapy molgramostim at the ATS International Conference in Orlando, Florida, May 17–20, 2026, the company announced.
The presentations will include results from the Phase 3 IMPALA-2 clinical trial evaluating molgramostim inhalation solution in patients with autoimmune pulmonary alveolar proteinosis, or aPAP, a rare lung disease.
Savara said one oral presentation and two poster sessions were accepted, including data from both the randomized trial and its ongoing open-label treatment period.
The oral presentation, scheduled for Monday, May 18, will focus on improvements in exercise distance and duration among aPAP patients treated with molgramostim.
Cormac McCarthy, an associate professor of medicine at University College Dublin and consultant respiratory physician at St. Vincent’s University Hospital, will present the findings.
Two poster presentations will follow, including data on long-term efficacy and safety of molgramostim from the open-label extension of the IMPALA-2 trial.
A second poster will examine the relationship between pulmonary gas transfer and biomarker levels in patients with aPAP.
The posters will be presented Tuesday, May 19, and Wednesday, May 20, at the Orange County Convention Center in Orlando.
Bruce Trapnell, professor of medicine and pediatrics at the University of Cincinnati College of Medicine, and Yoshikazu Inoue, executive director of the Clinical Research Center at NHO Kinki Chuo Chest Medical Center in Japan, will present the poster data.
Savara also said it will host an industry theater session on aPAP, covering disease mechanisms, diagnosis, and patient experience, led by Kevin Davidson and moderated by Jeff Sippel.
Autoimmune pulmonary alveolar proteinosis is a rare condition in which surfactant accumulates in the lungs due to impaired clearance by immune cells, leading to breathing difficulties and other complications.
Molgramostim is an inhaled form of granulocyte-macrophage colony-stimulating factor, designed to restore macrophage function and improve surfactant clearance.
Savara is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.